secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2023-07-24T23:59:59+00:00
Accession:  0001493152-23-025396
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 3.03, 5.03, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte implements 1-for-20 reverse stock split to regain Nasdaq compliance
----------------------------------------------------------------------------

- Reverse stock split at 1-for-20 effective 5:00 p.m. PT July 24, 2023; trading on split-adjusted basis July 25.
- Shareholders approved at special meeting July 24; Board determined ratio; authorized shares not reduced.
- Post-split shares approximately 8.24 million; fractional shares paid in cash at $4.3660 per pre-split share.
- Split intended to regain Nasdaq minimum bid price compliance; symbol remains OCX, CUSIP changes to 68235C206.
- Proportionate adjustments to convertible preferred, warrants, stock options, and equity plans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223025396/0001493152-23-025396-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223025396/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-025396

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer